Dyne Therapeutics (NASDAQ:DYN) Reaches New 52-Week Low – Here’s What Happened

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) reached a new 52-week low during mid-day trading on Saturday . The stock traded as low as $14.79 and last traded at $15.87, with a volume of 9825974 shares changing hands. The stock had previously closed at $23.05.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on DYN shares. Chardan Capital restated a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a report on Friday. StockNews.com lowered Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. Raymond James raised Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Royal Bank of Canada initiated coverage on shares of Dyne Therapeutics in a research report on Tuesday, November 26th. They issued an “outperform” rating and a $45.00 price target on the stock. Finally, Baird R W raised shares of Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. One analyst has rated the stock with a sell rating, one has issued a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.91.

Dyne Therapeutics Stock Down 31.1 %

The firm has a market capitalization of $1.62 billion, a price-to-earnings ratio of -4.46 and a beta of 1.16. The business has a 50-day moving average of $27.29 and a two-hundred day moving average of $34.15.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.25). Equities analysts predict that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, SVP Richard William Scalzo sold 1,455 shares of the stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total transaction of $40,914.60. Following the completion of the transaction, the senior vice president now directly owns 127,078 shares in the company, valued at $3,573,433.36. This represents a 1.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Oxana Beskrovnaya sold 2,334 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total transaction of $65,632.08. Following the completion of the sale, the insider now owns 201,685 shares in the company, valued at $5,671,382.20. This represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 44,742 shares of company stock valued at $1,443,246 over the last quarter. 20.77% of the stock is owned by company insiders.

Institutional Trading of Dyne Therapeutics

Several hedge funds have recently modified their holdings of DYN. JPMorgan Chase & Co. increased its stake in shares of Dyne Therapeutics by 4.3% in the third quarter. JPMorgan Chase & Co. now owns 101,750 shares of the company’s stock valued at $3,655,000 after buying an additional 4,236 shares in the last quarter. Virtue Capital Management LLC grew its holdings in Dyne Therapeutics by 4.4% during the 3rd quarter. Virtue Capital Management LLC now owns 23,208 shares of the company’s stock worth $834,000 after acquiring an additional 981 shares during the last quarter. Geode Capital Management LLC increased its position in Dyne Therapeutics by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,859,413 shares of the company’s stock valued at $66,802,000 after acquiring an additional 84,760 shares in the last quarter. Barclays PLC raised its stake in shares of Dyne Therapeutics by 162.2% in the third quarter. Barclays PLC now owns 207,309 shares of the company’s stock worth $7,446,000 after acquiring an additional 128,246 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Dyne Therapeutics during the third quarter worth approximately $1,067,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.